zidovudine has been researched along with Pancreatic Neoplasms in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoshino, T; Kodama, R; Mizushima, T; Moritomo, S; Namba, T | 1 |
| Chandrasekaran, B; Duch, DS; Kute, TE | 1 |
| Ansari, R; Gonin, R; Loehrer, PJ; McClean, J; Miller, KD; Mortimer, J; Pletcher, W; Spiridonidis, CH; Weber, G | 1 |
| Taniki, T; Weber, G; Zhen, YS | 1 |
| Nagai, M; Nakamura, H; Olah, E; Prajda, N; Szekeres, T; Weber, G | 1 |
1 trial(s) available for zidovudine and Pancreatic Neoplasms
| Article | Year |
|---|---|
A phase II study of weekly oral methotrexate and zidovudine (AZT) in advanced adenocarcinoma of the pancreas and hepatocellular carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Female; Humans; Liver Neoplasms; Male; Methotrexate; Middle Aged; Pancreatic Neoplasms; Remission Induction; Zidovudine | 1996 |
4 other study(ies) available for zidovudine and Pancreatic Neoplasms
| Article | Year |
|---|---|
Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Topics: Animals; Antimetabolites, Antineoplastic; Antiviral Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Survival; Deoxycytidine; Drug Resistance, Neoplasm; Equilibrative Nucleoside Transporter 1; Gemcitabine; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Pancreatic Neoplasms; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Snail Family Transcription Factors; Transcription Factors; Up-Regulation; Xenograft Model Antitumor Assays; Zidovudine | 2015 |
Synchronization of cells in the S phase of the cell cycle by 3'-azido-3'-deoxythymidine: implications for cell cytotoxicity.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Division; Cell Survival; Colonic Neoplasms; Computer Simulation; DNA, Neoplasm; Drug Synergism; Flow Cytometry; Fluorouracil; Humans; Leukemia; Melanoma; Methotrexate; Pancreatic Neoplasms; S Phase; Tumor Cells, Cultured; Zidovudine | 1995 |
Azidothymidine and dipyridamole as biochemical response modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells.
Topics: Adenocarcinoma; Cell Division; Cell Line; Cell Survival; Colonic Neoplasms; Dipyridamole; DNA Replication; Drug Screening Assays, Antitumor; Drug Synergism; Fluorouracil; Humans; Methotrexate; Pancreatic Neoplasms; Thymidine; Tumor Stem Cell Assay; Zidovudine | 1992 |
AZT: a biochemical response modifier of methotrexate and 5-fluorouracil cytotoxicity in human ovarian and pancreatic carcinoma cells.
Topics: Animals; Binding, Competitive; Cell Line; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluorouracil; Humans; Hypoxanthine; Hypoxanthines; In Vitro Techniques; Methotrexate; Ovarian Neoplasms; Pancreatic Neoplasms; Rats; Thymidine; Thymidine Kinase; Tumor Cells, Cultured; Zidovudine | 1991 |